神经科市场：BCC 研究概述

Neurology Market: A BCC Research Overview

出版日期: 2025年02月17日 | 出版商:

BCC Research | 英文 185 Pages | 订单完成后即时交付

价格

简介目录图表

全球神经科市场规模预计将从 2024 年的 673 亿美元增至 2029 年的 948 亿美元，预测期内的复合年增长率为 7.1%。

多发性硬化症领域预计将从 2024 年的 225 亿美元增加到 2029 年的 272 亿美元，复合年增长率为 3.9%。脑肿瘤学领域预计将从 2024 年的 29 亿美元增加到 2029 年的 53 亿美元，复合年增长率为 12.6%。

本报告调查了全球神经科市场，并提供了市场的全面概述、市场影响因素和市场机会的分析、法律制度、通路趋势、市场规模趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业的概况。

帕金森氏症药物企业市场占有率分析
阿兹海默症药物企业市场占有率分析
抗精神病药物企业市场占有率分析
抗癫痫药物企业市场占有率分析
泛自闭症障碍治疗药物企业市场占有率分析
脑肿瘤治疗药物企业市场占有率分析
多发性硬化症药物企业市场占有率分析

第 8 章附录

调查方法
来源
简称
公司简介
ABBVIE INC.
ALPHA COGNITION
BIOGEN
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
H. LUNDBECK A/S
LILLY
MERCK & CO. INC.
NOVARTIS AG
OTSUKA HOLDINGS CO. LTD.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB SA

简介目录图表

Product Code: PHM215B

The global market for neurology is estimated to increase from $67.3 billion in 2024 to reach $94.8 billion by 2029, at a compound annual growth rate (CAGR) of 7.1% from 2024 through 2029.

The multiple sclerosis market for neurology is estimated to increase from $22.5 billion in 2024 to reach $27.2 billion by 2029, at a CAGR of 3.9% from 2024 through 2029.

The brain tumor market for neurology is estimated to increase from $2.9 billion in 2024 to reach $5.3 billion by 2029, at a CAGR of 12.6% from 2024 through 2029.

Report Scope

This report includes a market analysis of the therapeutics used to treat neurological conditions. The study outlines the market potential for neurology medications for both now and in the future. It also provides a thorough examination of the market's drivers, constraints, and pipeline medications, as well as the competitive landscape, laws, epidemiology of neurological disorders, mergers and acquisitions. Market forecasts through 2029 are also covered in the report.

The report breaks down neurology market shares according to various disease indications. Parkinson's disease, Alzheimer's disease, psychotic disorder, epileptic disorder, autism disorder, multiple sclerosis, brain tumor, and other diseases are the neurological disorders that make up the market segmentation. Therapeutics and regional analysis are covered in each disease segment.

Anti-Parkinson's medications are covered in the Parkinson's disease market. The market is divided into different drug classes such as dopaminergic, enzyme inhibitors, dopamine agonists and other anti-Parkinson's drugs based on drug class. Anti-Alzheimer medications are part of the Alzheimer's disease market, which is divided into segments according to respective mechanisms of action. The market is divided into two segments based on drug class: NMDA antagonists and AChE inhibitors. Antipsychotic medications are part of the market for psychotic diseases. The market is divided into different drug classes, including D2 partial agonists, D2/5HT2A antagonists, and D2 antagonists.

Anti-epileptic medications are included in the market for epileptic diseases. The market is divided into three segments based on drug class: first-generation, second-generation and third-generation. Autism spectrum disorder drugs are included in the market. Based on information on labels, the market is divided into drug categories: off-label pharmaceuticals and pharmaceuticals with an ASD label. Brain tumor treatments are included in the market for brain tumors. The market is divided into different types of therapy, such as targeted therapy and chemotherapy.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. By geographical region, the market in this report is divided into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

Report Includes

52 data tables and 59 additional tables
Analyses of the global market trends for neurology therapeutics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
Estimates of the market size and revenue growth prospects, along with a market share analysis by type of disorder, drug classification, mechanism of action, label information, end user and region
Facts and figures pertaining to key market dynamics, technology advances, pipeline drugs, regulations, and the impact of macroeconomic factors
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
Pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage
Discussion of therapeutics used for treatment of neurological disorders, along with coverage of novel pipeline drugs, patent expiries of blockbuster drugs and new drug approvals
A patent analysis, including key granted and published patents
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Novartis AG, UCB S.A, and Otsuka Holdings Co. Ltd.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Porter's Five Forces Analysis
Potential for New Entrants (Low to Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate)
Threat of Substitute Products or Services (Moderate to High)
Industry Rivalry (High)
Medical Coding and Billing Challenges in Neurology
Step Therapy
Medicare Cuts
Coding errors
Use of Modifiers
Documentation
Coverage and Prior Authorization
Compliance and Audits
Reimbursement Rate and Denials
Physician Payment Challenges
Evaluation and Management (E/M) - Bill the Correct Level of Care
Negotiating Contracts

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Growing Geriatric Population with Neurological Disorders
Increasing Global Incidence of Neurological Disorders
Government and NGO Initiatives in Creating Awareness
Research Initiatives in Neurology
Market Restraints
Patent Expirations of Branded Drugs and Emergence of Generics
Adverse Side Effects
High Cost of Drug Development

Chapter 4 Emerging Trends and Pipeline Analysis

Emerging Trends
Precision Medicine in Neurological Disorders
Gene Therapy for Neurological Disorders
Neurodegeneration and Stem Cell Therapy
Nanotechnology in Neuroscience
Virtual Reality and Digital Therapeutics
Conclusion
Pipeline Analysis

Chapter 5 Regulatory Landscape

Overview
Cross-Disciplinary Value Story
High-Quality Patient-Reported Outcome Data
Impact of New EU and the U.S. Legislation
Conclusion

Chapter 6 Market Segmentation Analysis

Segmental Breakdown
Market Analysis by Disease Indication
Parkinson's Disease
Alzheimer's Disease
Psychotic Disorders
Epileptic Disorder
Autism Spectrum Disorder
Brain Tumor
Multiple Sclerosis
Others
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Competitive Intelligence

Company Share Analysis of Anti-Parkinson's Drugs
Company Share Analysis of Alzheimer's Disease Drugs
Company Share Analysis of Antipsychotic Drugs
Company Share Analysis of Anti-Epileptic Drugs
Company Share Analysis of ASD Therapeutics
Company Share Analysis of Brain Tumor Therapeutics
Company Share Analysis of Multiple Sclerosis Therapeutics

Chapter 8 Appendix

Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
ALPHA COGNITION
BIOGEN
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
H. LUNDBECK A/S
LILLY
MERCK & CO. INC.
NOVARTIS AG
OTSUKA HOLDINGS CO. LTD.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB S.A.

简介目录图表

List of Tables

Summary Table : Global Neurology Market, by Disease Indication, Through 2029
Table 1 : Navigate New Neurology-related Codes
Table 2 : Adverse Side Effects of Some Neurological Drugs
Table 3 : List of Some Clinical Trial Drugs for Parkinson's Disease in Phase 3 and 4
Table 4 : List of Some Clinical Trial Drugs for Alzheimer's Disease in Phase 3 and 4
Table 5 : List of Some Clinical Trial Drugs for Epilepsy Disorder in Phase 3 and 4
Table 6 : List of Some Clinical Trial Drugs for Autism Spectrum Disorders in Phase 3 and 4
Table 7 : List of Some Clinical Trial Drugs for Brain Tumors in Phase 3 and 4
Table 8 : List of Some Clinical Trial Drugs for Multiple Sclerosis in Phase 3 and 4
Table 9 : Global Neurology Market, by Disease Indication, Through 2029
Table 10 : Global Neurology Market for Anti-Parkinson's Drugs, by Drug Class, Through 2029
Table 11 : Global Neurology Market for Anti-Parkinson's Drugs, by Region, Through 2029
Table 12 : Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2029
Table 13 : Global Neurology Market for Alzheimer Drugs, by Region, Through 2029
Table 14 : Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2029
Table 15 : Some Novel Antipsychotic Drug Targets and Therapeutic Characteristics
Table 16 : Global Neurology Market for Antipsychotic Drugs, by Region, Through 2029
Table 17 : Global Neurology Market for Anti-Epileptic Drugs, by Drug Class, Through 2029
Table 18 : Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2029
Table 19 : Global Neurology Market for ASD Therapeutics, by Label Information, Through 2029
Table 20 : Global Neurology Market for ASD Therapeutics, by Region, Through 2029
Table 21 : Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2029
Table 22 : Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2029
Table 23 : FDA Approved DMTs
Table 24 : Global Neurology Market for Multiple Sclerosis Therapeutics, by Region, Through 2029
Table 25 : Global Neurology Market for Other Disease Therapeutics, by Region, Through 2029
Table 26 : Global Neurology Market, by Region, Through 2029
Table 27 : North American Neurology Market, by Disease Indication, Through 2029
Table 28 : North American Neurology Market, by Country, Through 2029
Table 29 : U.S. Neurology Market, by Disease Indication, Through 2029
Table 30 : Canadian Neurology Market, by Disease Indication, Through 2029
Table 31 : Mexican Neurology Market, by Disease Indication, Through 2029
Table 32 : European Neurology Market, by Disease Indication, Through 2029
Table 33 : European Neurology Market, by Country, Through 2029
Table 34 : German Neurology Market, by Disease Indication, Through 2029
Table 35 : U.K. Neurology Market, by Disease Indication, Through 2029
Table 36 : French Neurology Market, by Disease Indication, Through 2029
Table 37 : Spanish Neurology Market, by Disease Indication, Through 2029
Table 38 : Italian Neurology Market, by Disease Indication, Through 2029
Table 39 : Rest of European Neurology Market, by Disease Indication, Through 2029
Table 40 : Asia-Pacific Neurology Market, by Disease Indication, Through 2029
Table 41 : Asia-Pacific Neurology Market, by Country, Through 2029
Table 42 : Chinese Neurology Market, by Disease Indication, Through 2029
Table 43 : Japanese Neurology Market, by Disease Indication, Through 2029
Table 44 : Indian Neurology Market, by Disease Indication, Through 2029
Table 45 : Rest of Asia-Pacific Neurology Market, by Disease Indication, Through 2029
Table 46 : Rest of the World Neurology Market, by Disease Indication, Through 2029
Table 47 : Key Companies in Alzheimer's Generic Drug Market
Table 48 : Key Companies in Alzheimer's Branded Drug Market
Table 49 : Global Ranking of Leading Manufacturers of ASD Drugs
Table 50 : Information Sources in this Report
Table 51 : Abbreviations Used in the Global Neurology Market Report
Table 52 : AbbVie Inc.: Company Snapshot
Table 53 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 54 : AbbVie Inc.: Product Portfolio
Table 55 : AbbVie Inc: News/Key Developments, 2023 and 2024
Table 56 : Alpha Cognition: Company Snapshot
Table 57 : Alpha Cognition: Financial Performance, FY 2022 and 2023
Table 58 : Alpha Cognition.: Product Portfolio
Table 59 : Alpha Cognition: News/Key Developments, 2024
Table 60 : Biogen.: Company Snapshot
Table 61 : Biogen: Financial Performance, FY 2022 and 2023
Table 62 : Biogen: Product Portfolio
Table 63 : Biogen: News/Key Developments, 2023 and 2024
Table 64 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 65 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023
Table 66 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 67 : Boehringer Ingelheim International GmbH: News/Key Developments, 2024
Table 68 : Bristol-Myers Squibb Co.: Company Snapshot
Table 69 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 70 : Bristol-Myers Squibb Co.: Product Portfolio
Table 71 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
Table 72 : Eisai Co. Ltd.: Company Snapshot
Table 73 : Eisai Co. Ltd..: Financial Performance, FY 2022 and 2023
Table 74 : Eisai Co. Ltd.: Product Portfolio
Table 75 : Eisai Co. Ltd.: News/Recent Developments, 2023 and 2024
Table 76 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 77 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 78 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 79 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 80 : H. Lundbeck A/S: Company Snapshot
Table 81 : H. Lundbeck A/S: Financial Performance, FY 2022 and 2023
Table 82 : H. Lundbeck A/S: Product Portfolio
Table 83 : H. Lundbeck A/S: News/Key Developments, 2021 and 2024
Table 84 : Lilly: Company Snapshot
Table 85 : Lilly: Financial Performance, FY 2022 and 2023
Table 86 : Lilly: Product Portfolio
Table 87 : Lilly: News/Key Developments, 2024
Table 88 : Merck & Co. Inc.: Company Snapshot
Table 89 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 90 : Merck & Co. Inc.: Product Portfolio
Table 91 : Merck & Co. Inc.: News/Key Developments, 2023
Table 92 : Novartis AG: Company Snapshot
Table 93 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 94 : Novartis AG: Product Portfolio
Table 95 : Novartis AG: News/Key Developments, 2022 and 2023
Table 96 : Otsuka Holdings Co. Ltd.: Company Snapshot
Table 97 : Otsuka Holdings Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 98 : Otsuka Holdings Co. Ltd.: Product Portfolio
Table 99 : Otsuka Holdings Co. Ltd.: News/Key Developments, 2023 and 2024
Table 100 : Sanofi: Company Snapshot
Table 101 : Sanofi: Financial Performance, FY 2022 and 2023
Table 102 : Sanofi: Product Portfolio
Table 103 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 104 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 105 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 106 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021-2023
Table 107 : UCB S.A.: Company Snapshot
Table 108 : UCB S.A.: Financial Performance, FY 2022 and 2023
Table 109 : UCB S.A.: Product Portfolio
Table 110 : UCB S.A.: News/Key Developments, 2024

List of Figures

Summary Figure : Global Neurology Market Share, by Disease Indication, 2023
Figure 1 : Porter's Five Forces Analysis of the Neurology Market
Figure 2 : Market Dynamics of Neurology Market
Figure 3 : Breakdown of People Aging 65 or Older with Alzheimer's Dementia, 2024
Figure 4 : Global Burden of Conditions Affecting the Nervous System, 2021
Figure 5 : Pipeline Analysis of Some Neurological drugs, by Phases, 2024
Figure 6 : Global Neurology Market Share, by Disease Indication, 2023
Figure 7 : Global Neurology Market Share for Anti-Parkinson's Drugs, by Drug Class, 2023
Figure 8 : Global Neurology Market Share for Anti-Parkinson's Drugs, by Region, 2023
Figure 9 : Global Neurology Market Share for Alzheimer Drugs, by Mechanism of Action, 2023
Figure 10 : Global Neurology Market Share for Alzheimer Drugs, by Region, 2023
Figure 11 : Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2023
Figure 12 : Global Neurology Market Share for Antipsychotic Drugs, by Region, 2023
Figure 13 : Prevalence of Mental Illnesses in U.S. Adult Populations, 2023
Figure 14 : Global Neurology Market Share for Anti-Epileptic Drugs, by Drug Class, 2023
Figure 15 : Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2023
Figure 16 : Global Neurology Market Share for ASD Therapeutics, by Label Information, 2023
Figure 17 : Global Neurology Market Share for ASD Therapeutics, by Region, 2023
Figure 18 : Global Market Share of Brain and Central Nervous System Cases, both Sexes, by WHO Region, 2022
Figure 19 : Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2023
Figure 20 : Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2023
Figure 21 : Prevalence of Multiple Sclerosis Cases in Select Countries, 2019
Figure 22 : Global Neurology Market Share for Multiple Sclerosis Therapeutics, by Region, 2023
Figure 23 : Global Neurology Market Share for Other Disease Therapeutics, by Region, 2023
Figure 24 : Global Neurology Market Share, by Region, 2023
Figure 25 : North American Neurology Market, by Disease Indication, 2021-2029
Figure 26 : North American Neurology Market Share, by Country, 2023
Figure 27 : European Neurology Market, by Disease Indication, 2021-2029
Figure 28 : European Neurology Market Share, by Country, 2023
Figure 29 : Asia-Pacific Neurology Market, by Disease Indication, 2021-2029
Figure 30 : Asia-Pacific Neurology Market Share, by Country, 2023
Figure 31 : Rest of the World Neurology Market, by Disease Indication, 2021-2029
Figure 32 : Share of Major Players in Anti-Parkinson's Drugs Market, 2023
Figure 33 : Share of Major Players in Antipsychotic Drugs Market, 2023
Figure 34 : Share of Major Players in Anti-Epileptic Drugs Market, 2023
Figure 35 : Share of Major Players in Brain Tumor Therapeutics Market, 2023
Figure 36 : Share of Major Players in Multiple Sclerosis Therapeutics Market, 2023
Figure 37 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 38 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 39 : Biogen: Revenue Share, by Business Unit, FY 2023
Figure 40 : Biogen: Revenue Share, by Country/Region, FY 2023
Figure 41 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023
Figure 42 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023
Figure 43 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 44 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 45 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 46 : Eisai Co. Ltd.: Revenue Share, by Region/Country, FY 2023
Figure 47 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 48 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 49 : H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2023
Figure 50 : H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2023
Figure 51 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 52 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 53 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023
Figure 54 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023
Figure 55 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 56 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 57 : Otsuka Holdings Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 58 : Otsuka Holdings Co. Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 59 : Sanofi: Revenue Share, by Business Unit, FY 2023
Figure 60 : Sanofi: Revenue Share, by Country/Region, FY 2023
Figure 61 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 62 : UCB S.A.: Revenue Share, by Business Unit, FY 2023
Figure 63 : UCB S.A.: Revenue Share, by Country/Region, FY 2023